Research Article
Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment
Table 4
Analysis of factors influencing HEHDS-guided CR in AML.
| Factors | | Total CR% | CR rate/non-HEHDS guided (%) | CR rate/HEHDS guided (%) | values |
| Mutation | TP53 | 3/5 (60) | 1/2 (50) | 2/3 (66.67) | 0.667 | KIT | 5/12 (41.67) | 1/2 (50) | 4/10 (40) | 0.682 | NRAS | 5/20 (25) | 1/6 (16.67) | 4/14 (28.57) | 0.517 | FLT3-ITD | 9/23 (39.13) | 1/6 (16.67) | 8/17 (47.06) | 0.208 |
| Median WBC count | | 38/93 (40.9) | 9/29 (31) | 29/64 (45.3) | 0.142 | | 10/28 (35.7) | 0/7 (0) | 10/21 (47.6) | 0.027 |
| Median marrow blast % | <10 | 28/54 (51.9) | 5/14 (35.7) | 23/40 (57.5) | 0.137 | ≥10 | 20/67 (30) | 4/22 (18.2) | 16/45 (35.6) | 0.119 |
|
|